This concept was first demonstrated using Nutlin-3a, a small molecule antagonist of MDM2, which has shown antitumour activity in vitro and in vivo through activation of the p53 pathway in tumour cells that retain wild-type p53 [117]. The gene discussed is TP53; the disease is neoplasm.